

**Decision Point: GF/B42/EDP01: Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period**

The Board:

1. Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ERO1 (“Table 1”);
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

**This decision does not have material budgetary implications for operating expenses.**

**Table 1: Secretariat’s Recommendation on Additional Funding to Finance UQD from the 2017-2019 Allocation Period** - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Eritrea	Malaria	ERI-M-MOH	Portfolio Optimization	USD	18,442,129	1,000,000	19,442,129
2	Eswatini	TB/HIV	SWZ-C-NERCHA	Portfolio Optimization	USD	41,142,961	2,267,807	43,410,768
3	Kyrgyz Republic	TB/HIV	KGZ-C-UNDP	Portfolio Optimization	USD	20,959,824	1,197,668	22,157,492
4	Sudan	Malaria	SDN-M-MOH	Portfolio Optimization	USD	104,004,056	13,984,233	117,988,289